Abstract Number: PB0254
Meeting: ISTH 2021 Congress
Theme: COVID and Coagulation » COVID and Coagulation, Clinical
Background: Patients affected by COVID-19 are at risk of various venous and arterial thrombotic events, as well as embolic risks, the risk can vary from 17% to 78% according to the different published series. therefore, thromboprophylaxis must be imperative.
Aims: To assess the use of rivaroxaban as thromboprophylaxis in recovered COVID-19 patients who are at thrombotic risk
Methods: Descriptive and analytical study in patients who presented pneumonia due to COVID-19 in April and May 2020, who received LMWH during their hospital stay and at discharge with rivaroxaban 10mg/day for 2 months. D-dimer was measured at the beginning of the study and 1 month after discharge. Thrombotic or hemorrhagic episodes are controlled after 1 and 2 months of treatment (June – July 2020).
Results:
50 patients, women 40% and men 60%, with a median age of 42.9 years. 64% had mild pneumonia and 36% had severe pneumonia, mean initial D-dimer 556.5ng/ml, 56% had D-dimer ≥ 500ng/ml at the time of hospital admission. Baseline D-dimer values were significantly higher in severe pneumonia. In the follow-up at one and two months, we found that D-dimer values were significantly higher among patients with severe pneumonia and also, in this group of patients, the percentage of patients with D-dimer levels ≥ 500ng/mL in the first month of follow-up, was significantly higher in the group of patients who were hospitalized for severe pneumonia. During the first month of follow-up, there was a thrombotic event and a hemorrhagic event in the group of patients with severe pneumonia; By the second month of follow-up, there was a hemorrhagic event in the group with mild pneumonia, but this difference in frequencies was not statistically significant.
Conclusions: The incidence of thrombotic and hemorrhagic events was low, so the thromboprophylaxis scheme used in patients with recovered pneumonia due to COVID-19 is recommended. Rivaroxaban is safe to use like thromboprophylaxis.
To cite this abstract in AMA style:
Del Carpio-Orantes L, García-Méndez S, Sánchez-Diaz JS, Peniche-Moguel KG, Aparicio-Sánchez EE, Segura-Rodríguez OI, Aguilar-Silva A, García-Hernández O, Escobar-Huerta A, Ahumada-Zamudio A, Velasco-Caicero AR, González-Segovia O, Pacheco-Pérez EJ, Munguia-Sereno AE, Contreras-Sánchez ER, Hernández-Hernández SN, Medrano-Rios LJ, Rosas-Lozano AL. Oral Anticoagulation with Rivaroxaban as Thromboprophylaxis in Patients Recovered from COVID-19 Pneumonia in Veracruz, Mexico [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/oral-anticoagulation-with-rivaroxaban-as-thromboprophylaxis-in-patients-recovered-from-covid-19-pneumonia-in-veracruz-mexico/. Accessed March 21, 2024.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/oral-anticoagulation-with-rivaroxaban-as-thromboprophylaxis-in-patients-recovered-from-covid-19-pneumonia-in-veracruz-mexico/